High Risk of Recurrence Recruiting Phase 3 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0073206 (High Risk of Recurrence)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02260505Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)Prevention